Nadia Akhiyat

Nadia Akhiyat

Auto-generated profile, based on publicly available information

Nadia Akhiyat

Mayo Clinic

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
NANadia Akhiyat
Nadia Akhiyat
VVVlad Vasile
Vlad Vasile
AAAli Ahmad
Ali Ahmad
JSJaskanwal Deep Sara
Jaskanwal Deep Sara
VNValentina Nardi
Valentina Nardi
ALAmir Lerman
Amir Lerman
Background: Elevated plasma ceramides are independent predictors of cardiovascular disease and mortality in patients with advanced epicardial coronary artery disease. Our understanding of plasma ceramides in early epicardial coronary artery disease, however, remains limited. We examined the role of plasma ceramides in early coronary atherosclerosis characterized by coronary endothelial dysfunction. Methods and Results: Participants presenting with chest pain and nonobstructive epicardial coronary artery disease underwent coronary endothelial function. Patients (n=90) demonstrated abnormal coronary endothelial function with acetylcholine (≥20% decrease in coronary artery diameter or ≤50% increase in coronary blood flow). A total of 30 controls had normal coronary endothelial function. Concentrations of plasma ceramide 18:0 ( P =0.038), 16:0 ( P =0.021), and 24:0 ( P =0.019) differed between participants with normal and abnormal coronary endothelial function. Ceramide 24:0 (odds ratio [OR], 2.23 [95% CI, 1.07–4.66]; P =0.033) and 16:0 (OR, 1.91×10 6 [95% CI, 11.93–3.07×10 11 ]; P =0.018) were independently associated with coronary endothelial dysfunction. Among participants with endothelium‐dependent coronary dysfunction (n=78), ceramides 16:0 (OR, 5.17×10 5 [95% CI, 2.83–9.44×10 10 ]; P =0.033), 24:0 (OR, 2.98 [95% CI, 1.27–7.00]; P =0.012), and 24:1/24:0 (OR, 4.39×10 −4 [95% CI, 4×10 −7 –0.48]; P =0.030) were more likely to be elevated. Conclusions: The current study demonstrated an association between increased circulating ceramide levels and coronary endothelial dysfunction in the absence of epicardial coronary artery disease. This study supports the role of plasma ceramides as a potential biomarker or a therapeutic target for early coronary atherosclerosis in humans.

26 February 2024 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
YKYoshihisa Kanaji
Yoshihisa Kanaji
AAAli Ahmad
Ali Ahmad
JSJaskanwal Deep Singh Sara
Jaskanwal Deep Singh Sara
IOIlke Ozcan
Ilke Ozcan
NANadia Akhiyat
Nadia Akhiyat
ALAmir Lerman
Amir Lerman

1 May 2023 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
PDF file
NANadia Akhiyat
Nadia Akhiyat
TLTerra Lasho
Terra Lasho
MGMorsaleh Ganji
Morsaleh Ganji
TTTakumi Toya
Takumi Toya
CSChang-Xin Shi
Chang-Xin Shi
ALAmir Lerman
Amir Lerman
Background: Clonal hematopoiesis (CH) of indeterminate potential (CHIP) is a risk factor for cardiovascular disease. The relationship between CHIP and coronary microvascular dysfunction (CMD) is unknown. The current study examines the association between CHIP and CH with CMD and the potential relationships in risk for adverse cardiovascular outcomes. Methods: In this retrospective observational study, targeted next-generation sequencing was performed for 177 participants with no coronary artery disease who presented with chest pain and underwent routine coronary functional angiogram. Patients with somatic mutations in leukemia-associated driver genes in hematopoietic stem and progenitor cells were examined; CHIP was considered at a variant allele fraction ≥2%; CH was considered at a variant allele fraction ≥1%. CMD was defined as coronary flow reserve to intracoronary adenosine of ≤2. Major adverse cardiovascular events considered were myocardial infarction, coronary revascularization, or stroke. Results: A total of 177 participants were examined. Mean follow-up was 12±7 years. A total of 17 patients had CHIP and 28 had CH. Cases with CMD (n=19) were compared with controls with no CMD (n=158). Cases were 56±9 years, were 68% women, and had more CHIP (27%; P =0.028) and CH (42%; P =0.001) than controls. CMD was associated with independent risk for major adverse cardiovascular events (hazard ratio, 3.89 [95% CI, 1.21–12.56]; P =0.023), and 32% of this risk was mediated by CH. The risk mediated by CH was ≈0.5× as large as the direct effect of CMD on major adverse cardiovascular events. Conclusions: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.

10 October 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
NANadia Akhiyat
Nadia Akhiyat
EHElias Hellou
Elias Hellou
IOIlke Ozcan
Ilke Ozcan
GRGhazi Alabdul Razzak
Ghazi Alabdul Razzak
AHAmro Hajja
Amro Hajja
ALAmir Lerman
Amir Lerman
Endothelial dysfunction can be regarded as the earliest feature of vascular aging and may occur in individuals without traditional risk factors for cardiovascular disease. Once present, endothelial dysfunction is known to increase the risk for atherosclerosis, cardiovascular diseases and complications such as stroke or death. Identification of individuals with early features of vascular aging remains challenging and has fuelled investigative efforts to associated biologic, imaging, and digital markers with endothelial dysfunction. This review highlights emerging and traditional methods to identify patients with early endothelial dysfunction and summarizes available and experimental therapies aimed at mitigating the vascular aging process.

7 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
NANadia Akhiyat
Nadia Akhiyat
IOIlke Ozcan
Ilke Ozcan
RGRajiv Gulati
Rajiv Gulati
APAbhiram Prasad
Abhiram Prasad
TTTamara Tchkonia
Tamara Tchkonia
ALAmir Lerman
Amir Lerman
Background: Coronary microvascular dysfunction (CMD) represents an early functional characteristic of coronary vascular aging. Klotho (α‐klotho) is a circulating protein inversely linked to physiological aging. We examined low klotho as a potential marker for vascular aging in patients with CMD and no coronary artery disease. Methods and Results: Patients undergoing nonurgent angiogram for chest pain who had no coronary artery disease underwent invasive coronary microvascular and endothelial function testing. CMD was defined by ≤50% increase in coronary blood flow (percentage change in coronary blood flow) in response to intracoronary acetylcholine or coronary flow reserve ≤2. Fresh arterial whole blood was used to analyze circulating endothelial progenitor cells with flow cytometry. Stored arterial plasma was used for klotho analysis by ELISA. Participants with CMD (n=62) were compared with those without CMD (n=36). Those with CMD were age 55±10 years (versus 51±11 years; P =0.07) and 73% women (versus 81%; P =0.38). Traditional risk factors for coronary artery disease were similar between groups. Patients with CMD had less klotho (0.88±1.50 versus 1.75±2.38 ng/mL; P =0.03), and the odds of low klotho in CMD were significant in a logistic regression model after adjusting for traditional cardiovascular risk factors (odds ratio [OR], 0.80 [95% CI, 0.636–0.996]; P =0.05). Higher klotho was associated with higher numbers of endothelial progenitor cells with vascular regenerative potential (CD34 + and CD34 + CD133 + KDR + ). Among a subgroup of patients with atherosclerotic cardiovascular disease risk <5% (n=58), CMD remained associated with lower klotho (OR, 0.80 [95% CI, 0.636–0.996]; P =0.047). Conclusions: Klotho may be a biomarker for CMD and may be a therapeutic target for groups of patients without significant traditional cardiovascular risk.

29 May 2024 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
IHIkram U. Haq
Ikram U. Haq
NANadia Akhiyat
Nadia Akhiyat
NANader Al-Shakarchi
Nader Al-Shakarchi
KSKonstantinos Siontis
Konstantinos Siontis
SMSiva K. Mulpuru
Siva K. Mulpuru
AKAmmar M. Killu
Ammar M. Killu